Pharmachal Health Group is focused on research and development of pharmaceutical products. The Company has developed a range of human and veterinary preparations, including a breakthrough, patented, lignocaine-based, mini-emulsion spray for cut and wound treatment, "NOPAYNE*". Pharmachal is stepping up NOPAYNE for TGA registration and launch in 2022. *Nopayne is currently not-for-sale, nor approved for commercial sale. It has not been registered with the Therapeutic Goods Administration. It has, however, been used extensively in humanitarian and compounding environments.